- Home
- SKYH vs CRVS Comparison
SKYH vs CRVS Comparison
Compare SKYH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYH
- CRVS
- Stock Information
- Founded
- SKYH 2017
- CRVS 2014
- Country
- SKYH United States
- CRVS United States
- Employees
- SKYH N/A
- CRVS N/A
- Industry
- SKYH Military/Government/Technical
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- SKYH Industrials
- CRVS Health Care
- Exchange
- SKYH Nasdaq
- CRVS Nasdaq
- Market Cap
- SKYH 325.2M
- CRVS 305.4M
- IPO Year
- SKYH N/A
- CRVS 2016
- Fundamental
- Price
- SKYH $10.52
- CRVS $5.75
- Analyst Decision
- SKYH Strong Buy
- CRVS Strong Buy
- Analyst Count
- SKYH 3
- CRVS 4
- Target Price
- SKYH $14.83
- CRVS $15.00
- AVG Volume (30 Days)
- SKYH 104.9K
- CRVS 518.7K
- Earning Date
- SKYH 08-12-2025
- CRVS 08-07-2025
- Dividend Yield
- SKYH N/A
- CRVS N/A
- EPS Growth
- SKYH N/A
- CRVS N/A
- EPS
- SKYH N/A
- CRVS N/A
- Revenue
- SKYH $20,919,000.00
- CRVS N/A
- Revenue This Year
- SKYH $124.39
- CRVS N/A
- Revenue Next Year
- SKYH $83.05
- CRVS N/A
- P/E Ratio
- SKYH N/A
- CRVS N/A
- Revenue Growth
- SKYH 94.38
- CRVS N/A
- 52 Week Low
- SKYH $9.28
- CRVS $2.54
- 52 Week High
- SKYH $14.52
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- SKYH 52.98
- CRVS 65.10
- Support Level
- SKYH $10.20
- CRVS $5.28
- Resistance Level
- SKYH $10.89
- CRVS $5.64
- Average True Range (ATR)
- SKYH 0.40
- CRVS 0.30
- MACD
- SKYH 0.02
- CRVS 0.03
- Stochastic Oscillator
- SKYH 46.43
- CRVS 77.70
About SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).